- Warfarin
- Warfarin potassium
- Warfarin Q concentrate
- Warfarin sodium
- 129069-15-4Ceramide,1-O-[3-O-(N-acetyl-a-neuraminosyl)-b-D-galactopyranosyl]-, intramol. 1A1,2A-ester (9CI)
- 129075-49-61(2H)-Isoquinolinone,3,4-dihydro-5-methoxy-
- 129075-52-11(2H)-Isoquinolinone,5-amino-3,4-dihydro-, hydrochloride (1:1)
- 129075-56-51(2H)-Isoquinolinone,3,4-dihydro-5-methyl-
- 129077-51-62,2':6',2''-Terpyridine,4'-(4-nitrophenyl)-
- 129077-96-9L-Tyrosine-b-13C
- 129079-26-12-Tetradecen-4-one,1-hydroxy-, (E)- (9CI)
- 129085-76-31H-Imidazole-4-propanoicacid, a-[(1S)-1-amino-3-methylbutyl]-a-hydroxy-, (aR)-
- 129-09-9Vat Yellow 2
- 129101-19-5(R,R,R)-2-AZABICYCLO[3.3.0]OCTANE-3-CARBOXYLIC ACID, BENZYL ESTER
Hot Products
- 621-59-0Isovanillin
- 17199-29-0Benzeneaceticacid, a-hydroxy-, (aS)-
- 2295-31-02,4-Thiazolidinedione
- 626-55-13-Bromopyridine
- 120511-72-01,3-Benzenediacetonitrile, α1,α1,α3,α3,5-pentamethyl-
- 58-86-6D(+)-Xylose
- 455-14-1Benzenamine,4-(trifluoromethyl)-
- 37640-57-6Melamine cyanurate
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Warfarin sodium |
EINECS | 204-929-4 |
| CAS No. | 129-06-6 | Density | 1.307g/cm3 |
| PSA | 70.34000 | LogP | 4.04780 |
| Solubility | N/A | Melting Point |
approximate 161℃ |
| Formula | C19H16NaO4 | Boiling Point | 515.2oC at 760mmHg |
| Molecular Weight | 332.331 | Flash Point | 188.8oC |
| Transport Information | UN 1544 6.1/PG 2 | Appearance | white or yellowish powder |
| Safety | 53-36/37/39-45 | Risk Codes | 61-28 |
| Molecular Structure |
|
Hazard Symbols |
 T+
|
| Synonyms |
3-(a-Acetonylbenzyl)-4-hydroxycoumarinsodium;Aldocumar;Athrombin;Coumadin;Coumadine;Dimantil;Marevam;Orfarin;Panwarfin;Prothromadin;Simarc 2;Sodiumwarfarin;Sofarin;Tintorane;Varfine;Waran;Warfarina;Warfil 5;Zoocoumarin sodium salt;2H-1-Benzopyran-2-one,4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt (9CI);Coumarin, 3-(a-acetonylbenzyl)-4-hydroxy-, sodium salt (8CI); |
Article Data | 3 |
Warfarin sodium Chemical Properties
Molecular Structure:
.png)
Molecular Formula: C19H16NaO4
Molecular Weight: 331.3172
IUPAC Name: Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate
Synonyms of Warfarin sodium (CAS NO.129-06-6): (+-)-Warfarin sodium ; 3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin sodium salt ; Aldocumar ; Caswell No. 903A ; Coumadan Sodico ; Coumadin ; Coumadin sodium ; Coumadine ; Coumafene sodium ; Dicusat ; EINECS 204-929-4 ; EPA Pesticide Chemical Code 086003 ; Jantoven ; Marevam ; Marevan ; Orfarin ; Panwarfin ; Prothromadin ; Ratsul soluble ; Simarc ; Sodium coumadin ; Sodium warfarin ; Sodium, ((3-(alpha-acetonylbenzyl)-2-oxo-2H-1-benzopyran-4-yl)oxy)- ; Tintorane ; UNII-6153CWM0CL ; UniWarfin ; Varfine ; Waran ; Warcoumin ; Warfarin, sodium deriv. ; Warfarin, sodium salt ; Warfilone ; Zoocoumarin sodium salt ; 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt ; 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt (1:1) ; Coumarin, 3-(alpha-acetonylbenzyl)-4-hydroxy-, sodium salt
CAS NO: 129-06-6
Classification Code: Anticoagulant ; Drug / Therapeutic Agent ; Human Data ; Mutation data ; Reproductive Effect
H bond acceptors: 4
H bond donors: 1
Freely Rotating Bonds: 5
Polar Surface Area: 63.6 Å2
Warfarin sodium Uses
Warfarin sodium (CAS NO.129-06-6) is used as Anti-clotting drug.
Warfarin sodium Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| chicken | LD50 | intravenous | 200mg/kg (200mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BLOOD: HEMORRHAGE SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. |
| child | TDLo | oral | 4mg/kg (4mg/kg) | BLOOD: CHANGES IN CELL COUNT (UNSPECIFIED) | American Journal of Diseases of Children. Vol. 147, Pg. 609, 1993. |
| dog | LD50 | intravenous | 200mg/kg (200mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BLOOD: HEMORRHAGE SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. |
| dog | LD50 | oral | 200mg/kg (200mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. |
| guinea pig | LD50 | oral | 182mg/kg (182mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. |
| guinea pig | LDLo | intravenous | 543mg/kg (543mg/kg) | Therapie. Vol. 18, Pg. 921, 1963. | |
| mouse | LD50 | intravenous | 160mg/kg (160mg/kg) | "Handbook of Analytical Toxicology," Sunshine, I., ed., Cleveland, OH, Chemical Rubber Co., 1969Vol. -, Pg. 123, 1969. | |
| mouse | LD50 | oral | 374mg/kg (374mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. |
| rabbit | LD50 | intravenous | 100mg/kg (100mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BLOOD: HEMORRHAGE SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. |
| rabbit | LD50 | oral | 800mg/kg (800mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. |
| rat | LD50 | intravenous | 25mg/kg (25mg/kg) | "Handbook of Analytical Toxicology," Sunshine, I., ed., Cleveland, OH, Chemical Rubber Co., 1969Vol. -, Pg. 123, 1969. | |
| rat | LD50 | oral | 8700ug/kg (8.7mg/kg) | BLOOD: HEMORRHAGE | Pharmacological Research Communications. Vol. 10, Pg. 445, 1978. |
| women | TDLo | oral | 300ug/kg/2D (0.3mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Archives of Dermatology. Vol. 116, Pg. 444, 1980. |
Warfarin sodium Consensus Reports
Reported in EPA TSCA Inventory. EPA Extremely Hazardous Substances List.
Warfarin sodium Safety Profile
Safety Information of Warfarin sodium (CAS NO.129-06-6):
Hazard Codes:T+ 
Risk Statements:61-28
Safety Statements:53-36/37/39-45
RIDADR:UN 1544 6.1/PG 2
WGK Germany:1
RTECS:GN4725000
HazardClass:6.1(a)
PackingGroup:II
Poison to humans by ingestion. Experimental poison by ingestion and intravenous routes. Human systemic effects by ingestion: dermatitis. Human reproductive effects by ingestion: fetotoxicity, abnormal condition of newborn at birth, other newborn physical effects, and teratogenic effects including developmental abnormalities of the eye and ear, craniofacial area, skin and appendages, musculoskeletal system, cardiovascular system, and gastrointestinal system of the fetus. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. An anticoagulant drug. When heated to decomposition it emits toxic fumes of Na2O.
Warfarin sodium Specification
First Aid Measures of Warfarin sodium (CAS NO.129-06-6):
Ingestion:Give water and induce vomiting. Never give anthing to an unconscious person. Obtain medical attention.
Inhalation:Remove to fresh air. Give CPR and/or oxygen if required.
Skin:Wash with soap and water.
Eyes:Flush with water for 15 minutes.
Storage of Warfarin sodium (CAS NO.129-06-6):
Store at away from heat and open flame. Do not store near feeds and foodstuffs and keep away from children, domestic animals, pets, or wildlife.
What can I do for you?
Get Best Price
